10x Genomics Q2 Revenue Drops 13% as Patent Settlement Windfall Fades; New IP Suits Filed
TXG has more than doubled off its 52-week low of $11.16.
Summary
10x Genomics posted a Q2 net loss of $17.9M as patent settlement revenue vanished, while core product growth remained sluggish. New IP lawsuits and insider trading plans add uncertainty.
Key Events · Earnings and Guidance · TXG
-
Q2 Net Loss of $17.9M
The bottom line swung to a net loss of $17.9M from net income of $34.5M in Q2 2025, driven by a 93% plunge in license and royalty revenue to $1.9M as one-time patent settlement gains from 2025 did not recur.
-
Revenue Declines 13% YoY
Total revenue fell to $151M from $172.9M, with products and services revenue up only 3% to $149.1M. Consumables grew 7%, but instrument revenue dropped 47%.
-
Gross Margin Improves to 74%
Gross margin expanded to 74% from 72%, helped by lower manufacturing costs, $2.6M in tariff refunds, and lower inventory write-downs, partially offsetting the revenue decline.
-
New IP Lawsuits Filed and Defended
The company filed patent infringement suits against Element Biosciences in the U.S. and Europe. Separately, Spatial Genomics and Caltech countersued, alleging Xenium platform infringement and seeking injunctive relief and unspecified damages.
Analysis · TXG · Industrial Applications And Services
A sharp reversal in profitability marks the quarter, as 10x Genomics swung to a $17.9M net loss from a $34.5M profit a year ago. The culprit: one-time license and royalty revenue from patent settlements evaporated, while core product and service revenue inched up only 3%. Operating expenses surged 39% without the prior year's large settlement gains. The company is aggressively defending its intellectual property, filing new suits against Element Biosciences and facing a countersuit from Spatial Genomics over its Xenium platform. Meanwhile, the acquisition of Proteintech Genomics adds proteomics capabilities, though the deal is small relative to the $5.8B market cap. Adding to the uncertainty, the CFO and a director adopted 10b5-1 trading plans, signaling planned insider sales.
At the time of this filing, TXG was trading at $43.07 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $11.16 to $50.34. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.